Moving beyond angiotensin II to also target aldosterone?
Little
William C
WC
Kirkman
Paul M
PM
D000450:Aldosterone / Q000096:biosynthesis; D000804:Angiotensin II / Q000096:biosynthesis*; D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D002318:Cardiovascular Diseases / Q000503:physiopathology*; D004359:Drug Therapy, Combination; D006801:Humans; D012084:Renin-Angiotensin System / Q000187:drug effects*; D012307:Risk Factors
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000804:Angiotensin II; D000450:Aldosterone